Abstract
Introduction
The aim of this study was to compare outcomes of topography-guided laser-assisted in situ keratomileusis (TG-LASIK) and small incision lenticule extraction (SMILE®) for correcting myopia and myopic astigmatism.
Methods
In this prospective, randomized contralateral study, 34 patients (68 eyes) received TG-LASIK in one eye, and SMILE in their fellow eye. Efficacy, safety, predictability, higher-order aberrations, corneal tomography, biomechanics, and patient-reported outcomes (PROs) were assessed preoperatively and up to 3 months postoperatively.
Results
Both platforms showed comparable efficacy at 3 months (TG-LASIK 1.08 ± 0.19; SMILE 0.98 ± 0.17, p = 0.055). However, TG-LASIK demonstrated quicker visual recovery, with 63% and 89% achieving uncorrected distance visual acuity (UDVA) of 20/16 or better at 1 day and 1 week, respectively, compared to SMILE (34% and 63%; p < 0.05). Safety index at 3 months did not significantly differ between TG-LASIK and SMILE (p = 0.223). TG-LASIK and SMILE had 44% and 56% of eyes within 0.13 D of spherical equivalent (SEQ) target, respectively. SMILE induced more total higher-order aberrations (HOAs), vertical coma, and oblique trefoil than TG-LASIK at 3 months (p < 0.05). Both platforms showed similar increases in epithelial remodeling, but SMILE induced thicker epithelium than TG-LASIK at the 7.0-mm nasal zonal area. No significant differences were found in corneal hysteresis (CH) or corneal resistance factor (CRF) at 3 months (p > 0.05). Reported symptoms of glare, halos, rings, starbursts, or dry eye did not significantly differ between groups at 3 months (p > 0.05). Overall, 59% of patients preferred their TG-LASIK treated eye at 1 month, but 65% of patients had no specific eye preference at 3 months.
Conclusion
TG-LASIK and SMILE demonstrate excellent and comparable efficacy, safety, and predictability at 3 months, but TG-LASIK offers faster postoperative visual recovery at 1 day and 1 week. TG-LASIK induces fewer HOAs than SMILE, but both procedures affect corneal biomechanics similarly.
Trial Registration
ClincialTrials.gov identifier, NCT05611294.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
Why carry out this study? |
This prospective, contralateral study compares outcomes of topography-guided LASIK (TG-LASIK) and small incision lenticule extraction (SMILE®) for correcting myopia and myopic astigmatism. |
Differences in safety, efficacy, predictability, higher-order aberrations (HOAs), corneal tomography, corneal biomechanics, and patient-reported outcomes (PROs) between the two platforms were assessed. |
What was learned from the study? |
TG-LASIK offered faster postoperative visual recovery at 1 day and 1 week, but both groups were similar in efficacy, safety, and predictability at 3 months postoperatively. SMILE induced more total HOAs, vertical coma, and oblique trefoil than TG-LASIK, but both groups affected corneal biomechanics similarly. |
Both platforms provide patients with excellent visual outcomes 3 months postoperatively. TG-LASIK induces less irregular astigmatism than SMILE owing to its enhanced cyclotorsion and centration control. |
Introduction
Corneal refractive surgeries, such as laser-assisted in situ keratomileusis (LASIK) and keratorefractive lenticule extraction (KLEx), have become increasingly popular as the prevalence of myopia has increased globally [1]. In response to this rise, many advancements in excimer laser platforms have been made to make these procedures more accurate, effective, and safer for patients [2]. WaveLight® Contoura Vision topography-guided LASIK (TG-LASIK), approved by the US Food and Drug Administration (FDA) in 2016, utilizes preoperative corneal topography measurements in its excimer laser platform to create a customized ablation to maintain the aspheric corneal shape and minimize surgically induced corneal irregularities [3, 4].
KLEx has been a viable alternative to traditional femtosecond-assisted LASIK, as it boasts a “flapless” approach and avoids flap-related complications [5]. Although studies have demonstrated that KLEx and LASIK provide patients with similar postoperative visual outcomes [6, 7], KLEx may also potentially induce less iatrogenic dry eye in the early postoperative period and may better maintain the cornea’s biomechanical properties [8, 9]. However, these findings have been controversial among other studies.
Several studies have compared visual and refractive outcomes and higher-order aberrations (HOAs) of TG-LASIK and KLEx [4, 10,11,12,13]. One study also assessed epithelial remodeling between these two procedures [14]; however, to the best of our knowledge, no studies have evaluated corneal biomechanics or extensive corneal topographic parameters between these two procedures. In this prospective, contralateral study, we aim to assess and compare visual and refractive outcomes, HOAs, various corneal tomographic parameters such as corneal and epithelial thickness, and corneal biomechanics of TG-LASIK and KLEx.
Methods
This is a single-center randomized, prospective contralateral controlled trial that was conducted at the Hoopes Vision Research Center in Draper, Utah (NCT05611294). This study was approved by the Salus Institutional Review Board (IRB) (IORG00005674) and adhered to the tenets of the Declaration of Helsinki. Informed consent was provided and documented in written form from each patient prior to the start of intervention.
Thirty-four patients (68 total eyes) with myopia (− 7.5 D to − 0.75 D) with or without astigmatism (− 2.75 D to 0 D) were recruited for participation in this study. To be eligible for inclusion, all patients met the following criteria: age of 22–50 at the time of consent, diagnosed with myopia or myopia with astigmatism with a preoperative spherical equivalent (SEQ) greater than or equal to − 2.00 and smaller than or equal to − 9.00 D, a preoperative spherical component of greater than or equal to − 2.00 and less than or equal to − 8.00 D, a refractive cylinder of greater than or equal to − 3.00 D, corrected distance visual acuity (CDVA) of 20/20 or better in each eye, a stable refraction defined as a change in SEQ no greater than 0.50 D comparing the screening visit manifest refraction to previous refractions over a 1-year period prior to surgery. Patients meeting any of the following criteria for either eye were excluded from the study: clinically significant dry eye, irregular astigmatism, keratoconus, abnormal corneal topography, a history of corneal dystrophies or guttata, herpetic keratitis or active disease, prior refractive surgery, glaucoma or glaucoma suspect, uncontrolled diabetes, unstable hypertension, unstable autoimmune disease, or female patients who were pregnant, breastfeeding, or intending to become pregnant at any time during the study, as determined by verbal inquiry. Subjects were then randomized to receive TG-LASIK in one eye and small incision lenticule extraction (SMILE®) in the contralateral eye via selection of sealed envelopes containing cards indicating one of the two choices for right eye treatment. Card selection was done at the time of surgery scheduling.
All patients received a complete preoperative ophthalmic evaluation which included uncorrected distance visual acuity (UDVA), CDVA, best corrected 25% and 5% contrast sensitivity testing under mesopic conditions (without glare), intraocular pressure (IOP), slit lamp examination, dilated fundus examination, manifest refraction, and keratometry. Corneal topographic mapping and Zernike analysis for HOAs (total HOAs, spherical aberration (SA), horizontal/vertical coma, horizontal/oblique trefoil) were performed with a Pentacam HR (Oculus, Arlington, WA, USA). Corneal pachymetry was obtained with the Avanti Widefield optical coherence tomography (OCT) system (Optovue, Fremont, CA, USA) and corneal biomechanics were measured with the Ocular Response Analyzer® G3 (ORA) (Reichert Technologies, Depew, NY, USA). Patients were also provided with an adaptation of the Quality of Vision (QoV) [15] questionnaire to assess the following qualities both preoperatively and postoperatively: glare, disabling halos/rings/starbursts, dry-eye issues, and eye preference.
Patients were evaluated postoperatively at 1 day, 1 week, 1 month, and 3 months. Visual acuity was measured at each visit. Refractive outcomes and corneal tomography were measured at 1 week, 1 month, and 3 months. Contrast sensitivity, corneal biomechanics, and patient-reported outcomes (PROs) were measured at 1 and 3 months. HOAs were evaluated only at 3 months.
Surgical Interventions
Both TG-LASIK and SMILE were performed sequentially on each subject on the same day by a single surgeon (MM) with 26 and 8 years of experience in performing LASIK and SMILE, respectively. Prior to starting TG-LASIK, multiple topographical measurements with the WaveLight® VARIO Topolyzer (Alcon Laboratories, Inc., Fort Worth, TX, USA) were utilized for corneal mapping for customized ablation treatment. At least four of these measurements were chosen on the basis of mean deviation. VARIO results were uploaded into the Phorcides Analytic Engine (PAE) (Phorcides LLC, St. Paul, MN, USA) for further precision and customization of the ablation pattern to account for corneal asymmetry. The updated VARIO results were then relayed to the WaveLight® EX500 Excimer Laser (Alcon Laboratories Inc., Fort Worth, TX, USA) for stromal ablation. The FS200 femtosecond laser system was used to create a superiorly hinged corneal flap with an 8.9-mm diameter and 100 µm thickness. The following laser settings were used: 0.72 µJ laser-bed energy, 7.0 µm bed spot/line, 0.72 µJ side-cut energy, and 5.0/3.0 µm side-cut spot/line.
For SMILE, our previously established nomogram from Datagraph-med® version 5.80 (Datagraph, Chapel Hill, NC, USA) based on 1-year outcomes was used for target spherical and cylindrical correction. Patients with a cylinder of ≤ 0.50 D underwent myopic SMILE based on SEQ, whereas those with a cylinder of ≥ 0.75 D received myopic astigmatic SMILE based on nomogramic data. The VisuMax 500 kHz femtosecond laser system (Carl Zeiss Meditec AG, Jena, Germany) was used with pulse durations of 220–580 fs and with the following laser parameters: 3.9 mm superior corneal incision, small cone size, 7.5 mm cap diameter, 120 µm cap thickness, 6.0–6.5 mm lenticule diameter, superior incision position, 90° side-cut angle, 50° incision angle, laser-bed energy of 145 nJ, and 3 µm, 2.5 µm, 3 µm, and 2 µm spot separations for the lenticule, lenticule side-cut, cap, and incision side-cut, respectively.
After completion of both procedures, patients received one drop of moxifloxacin 0.5% ophthalmic solution eye drops in both eyes. The postoperative drop regimen included moxifloxacin four times daily for 1 week in both eyes, prednisolone acetate 1% ophthalmic suspension drops four times daily for 1 week in both eyes, and twice daily for an additional 2 weeks in the SMILE eye. Preservative-free artificial tears were used as needed.
Statistical Analysis
Statistical analysis was conducted using Excel (Microsoft Corporation, Redmond, WA, USA) and Statistical Package for the Social Sciences (SPSS) version 27.0.0.0 (IBM, Armonk, NY, USA). Variable distributions were evaluated for normality with Kolmogorov–Smirnov and Shapiro–Wilk testing. Non-normalized variables were treated with transformations for use in statistical testing. Homogeneity of variances were tested with Levene’s test. A significance level of above 0.05 was used to judge acceptable normality and homogeneity. Multicollinearity analysis was performed to observe the variance inflation factor, of which no variable surpassed a threshold of five, signifying no excessive correlations. Chi-square testing was performed for comparisons between categorical variables. Analysis of variance (ANOVA) with post hoc Tukey testing was conducted on preoperative variables between the two surgery groups to evaluate for differences. Two-way analysis of covariance (ANCOVA) testing with pairwise comparisons was performed in multivariate fashion on all postoperative variables, with repeated measures versions used when necessary. Factors utilized were surgery type and time. All ANCOVA models incorporated covariates of age and sex to compensate for their effects on postoperative outcomes. ANCOVA models had general power above 0.99 and powers above 0.8 for each reported variable observation. Bonferroni corrections were used in estimated marginal mean calculation with pairwise comparison in ANCOVA testing to decrease type I errors. Standard refractive surgery graphs were created, and vector analysis was performed using mEYEstro (MathWorks Inc, Natick, MA, USA) [16] and astigMATIC software (McGill University, Montreal QC, Canada) [17], respectively. Cylinder is depicted in these materials with negative notation converted to positive notation. A threshold of 0.05 was used to define statistical significance for reported observations.
Results
Preoperative Characteristics
The mean age of patients was 34 ± 6 years (range 22–49 years) and included 14 male (41%) and 20 female (59%) participants. Thirty-four eyes were treated with TG-LASIK and the contralateral 34 eyes were treated with SMILE. The patients’ demographics and preoperative characteristics are summarized in Table 1. There were no significant differences in age, sex, UDVA, SEQ, sphere, cylinder, mean anterior keratometry (Km), central corneal thickness (CCT), total HOAs, spherical aberration (SA), horizontal/vertical coma, horizontal/oblique trefoil, corneal hysteresis (CH), or corneal resistance factor (CRF) between the two groups (p > 0.05).
Visual Outcomes
For both groups, 97% of patients achieved a UDVA of 20/20 or better at 3 months (Fig. 1a). Additionally, a greater percentage of TG-LASIK eyes achieved a UDVA of 20/16 and 20/12.5 compared to SMILE eyes at 3 months, although the intergroup differences were not significant (p > 0.05). However, at 1 day, the TG-LASIK group demonstrated a quicker visual recovery, with 100%, 63%, and 37%, and 6% of eyes seeing 20/20, 20/16, and 20/12.5, and 20/10, respectively, compared to 66%, 34%, 3%, and 0% of eyes in the SMILE group, respectively (p < 0.05) (Fig. 2). Similar findings were seen at 1 week, with 100%, 89%, 34%, and 3% of TG-LASIK eyes seeing 20/20, 20/16, 20/12.5, and 20/10, respectively, compared to 86%, 63%, 11%, and 0% of eyes in the SMILE group, respectively (p < 0. 05).
With regards to efficacy, there was a statistical tendency for the TG-LASIK group to be more efficacious than the SMILE group at 3 months (1.08 ± 0.19 vs. 0.98 ± 0.17; p = 0.055) (Fig. 1b). At 3 months, 91% of TG-LASIK and 71% of SMILE eyes saw the same number of lines or better of UDVA compared to preoperative CDVA. The TG-LASIK group had a better safety profile than the SMILE group, although these findings were not significant (1.17 ± 0.16 vs. 1.12 ± 0.18; p = 0.223) (Fig. 1c).
Both groups had significant improvements in 25% contrast sensitivity from preoperative to 3 months (TG-LASIK 0.59 ± 0.07 to − 0.06 ± 0.09, p < 0.001; SMILE 0.59 ± 0.08 to − 0.03 ± 0.08; p < 0.001) (Table 2); however, TG-LASIK eyes had significantly better 25% contrast readings at 1 month compared to SMILE eyes (− 0.06 ± 0.06 vs. 0.00 ± 0.09; p = 0.001). Similarly, both groups had significant improvements in 5% contrast sensitivity from preoperative to 3 months (TG-LASIK 0.86 ± 0.11 to 0.23 ± 0.14, p < 0.001; SMILE 0.88 ± 0.13 to 0.23 ± 0.13, p < 0.001); however, TG-LASIK eyes had significantly better 5% contrast readings at 1 month compared to SMILE eyes (0.20 ± 0.09 vs. 0.33 ± 0.15; p < 0.001). There were no significant intergroup differences in contrast sensitivity at 3 months (p > 0.05).
Refractive Outcomes
Both groups had significant improvements in mean SEQ from the preoperative period to 3 months (p < 0.001) (Table 3). Both groups had significant improvements in mean SEQ from the preoperative period to 1 week (p < 0.001) and remained stable from 1 week to 3 months (p > 0.05). The TG-LASIK group had a significantly more hyperopic SEQ at 1 month compared to the SMILE group (0.28 ± 0.27 D vs. 0.13 ± 0.31 D; p = 0.042); however, there were no significant intergroup differences at 3 months (0.16 ± 0.26 D vs. 0.17 ± 0.24 D; p = 0.966). In terms of predictability, 44% of TG-LASIK eyes and 56% of SMILE eyes were within ± 0.13 D of SEQ target at 3 months (Fig. 1d). Linear regression analysis of attempted vs. achieved SEQ showed a mean regression value of 1.00x − 0.16 D (R2 = 0.98) for TG-LASIK eyes and 0.95x + 0.37 D (R2 = 0.98) for SMILE eyes (Fig. 1e). SEQ was stable for both groups throughout the postoperative period, with only 3% (one eye) of TG-LASIK eyes and 0% of SMILE eyes having a > 0.50 D change from 1 to 3 months (Fig. 1f).
Both groups had significant improvements in cylindrical astigmatism from the preoperative period to 3 months (p < 0.05) (Table 3). Both groups had significant improvements in astigmatism from the preoperative period to 1 week (p < 0.001) and remained stable from 1 week to 3 months (p > 0.05). Residual astigmatism was significantly lower in the TG-LASIK group compared to the SMILE group at 3 months (− 0.20 ± 0.20 D vs. − 0.31 ± 0.22 D; p = 0.039), with 100% of TG-LASIK eyes and 88% of SMILE eyes achieving ≤ 0.50 D (Fig. 1g). Linear regression analysis of target vs. surgically induced astigmatism showed a mean regression value of 0.82x + 0.09 D (R2 = 0.87) for TG-LASIK eyes and 0.66x + 0.32 D (R2 = 0.37) for SMILE eyes (Fig. 1h), with a difference vector mean of 0.08 D × 161° for TG-LASIK eyes and 0.13 D × 2° for SMILE eyes (Fig. 3). MEYEstro and astigMATIC analysis showed that TG-LASIK had a correction index (CI) of 0.90 and 0.98, respectively, whereas SMILE had a CI of 0.99 and 1.06, respectively (Fig. 1i, Fig. 3). However, the intergroup differences were not significant (p = 0.309; p = 0.102). There were also no significant intergroup differences in angle of error (2.87 ± 15.02° vs. 1.63 ± 9.42°; p = 0.287).
Corneal Higher-Order Aberrations (HOAs)
Both groups had a significant increase in total HOAs from the preoperative period to 3 months (TG-LASIK 0.33 ± 0.08 µm to 0.42 ± 0.13 µm, p = 0.014; SMILE 0.34 ± 0.08 µm to 0.52 ± 0.18 µm, p < 0.001) (Table 4); however, the TG-LASIK group had significantly lower total HOAs than the SMILE group (difference = 0.09 µm, [0.02–0.18]; p = 0.014) (Fig. 4). There were no significant increases in spherical aberration (SA), horizontal/vertical coma, or horizontal/oblique trefoil in the TG-LASIK group at 3 months (p > 0.05), whereas the SMILE group had significant increases in vertical coma (− 0.04 ± 0.15 µm to − 0.21 ± 0.19 µm; p < 0.001) and oblique trefoil (− 0.07 ± 0.10 µm to − 0.01 ± 0.12 µm; p = 0.022). Additionally, The TG-LASIK group had a lower amount of vertical coma than the SMILE group at 3 months (difference = 0.19 µm, [0.10–0.28]; p < 0.001) (Fig. 4).
Corneal Epithelial Map Analysis
Central corneal epithelial thickness (CET) significantly increased for both groups from the preoperative period to 3 months (TG-LASIK 54.11 ± 2.63 µm to 56.30 ± 3.70 µm, p = 0.037; SMILE 53.77 ± 3.02 µm to 57.00 ± 3.85 µm, p < 0.001), with no significant intergroup differences at any time point (p > 0.05) (Table 5). For the TG-LASIK group, central CET significantly increased from preoperative to 1 month (p < 0.001) and remained stable from 1 to 3 months (p > 0.05). For the SMILE group, central CET was stable from preoperative to 1 month (p > 0.05), and then had a significant increase from 1 month to 3 months (p = 0.048).
For the TG-LASIK group, there was a significant increase in all quadrants (superior, inferior, nasal, temporal) of CET at the 5.0-mm and 7.0-mm zonal area (p < 0.05), except for superior, nasal, and temporal at 7.0 mm (p > 0.05) from preoperative to 3 months (Table 5). For the SMILE group, there was a significant increase in all quadrants at the 5- and 7.0-mm zonal area (p < 0.05) except for superior-7.0 mm (p = 0.141). At 3 months, the SMILE group had a significantly higher nasal CET at 7.0 mm compared to the TG-LASIK group (57.1 ± 3.8 µm vs. 55.1 ± 4.0 µm, p = 0.04) (Fig. 5). Additionally, the SMILE group had a significantly greater increase in nasal CET at 7.0 mm compared to the TG-LASIK group (3.7 ± 2.8 µm vs. 1.3 ± 2.8 µm; p = 0.001).
Maximum (max) CET for both groups significantly increased from preoperative to 3 months (p < 0.001), with an early significant increase from preoperative to 1 week (p < 0.001) (Table 6). The SMILE group also experienced an additional significant increase from 1 month to 3 months (p = 0.028). Intergroup differences were insignificant with the exception at 1 month (p = 0.030). Minimum (min) CET was stable throughout the postoperative period for the TG-LASIK group (p > 0.05), but significantly decreased from preoperative to 1 week (p = 0.04) and 1 month (p = 0.002) for the SMILE group. However, there were no significant intergroup differences at any time point (p > 0.05).
The difference between max and min (max − min) CET for both groups significantly increased from preoperative to 3 months (TG-LASIK 9.12 ± 4.88 µm to 15.49 ± 5.26 µm, p < 0.001; SMILE 8.34 ± 4.60 µm to 16.07 ± 4.91 µm, p < 0.001). Both groups experienced an early significant increase in the early postoperative period from preoperative to 1 week (p < 0.001); however, there were no significant intergroup differences at any time point (p > 0.05). With regards to variability of CET (SD CET), both groups had a significant increase in SD CET from preoperative to 3 months (TG-LASIK 1.83 ± 0.77 µm to 3.51 ± 1.33 µm, p < 0.001; SMILE 1.65 ± 0.64 µm to 3.38 ± 1.02 µm, p < 0.001), with the greatest change early in the postoperative period from preoperative to 1 week (p < 0.001). There were no significant intergroup differences in SD CET at any time point (p > 0.05).
Corneal Biomechanics
Both TG-LASIK and SMILE showed a significant decrease in CH from preoperative to 3 months (TG-LASIK 10.04 ± 1.32 mmHg to 7.81 ± 1.23 mmHg, p < 0.001; SMILE 9.90 ± 1.57 mmHg to 8.20 ± 1.44 mmHg, p < 0.001) (Fig. 6). Both groups experienced a significant decrease in CH from preoperative to 1 month (p < 0.001) which remained stable from 1 to 3 months (p > 0.05). Similarly, there was a significant decrease in CRF from preoperative to 3 months for both groups (TG-LASIK 10.25 ± 1. 67 mmHg to 6.53 ± 1.31 mmHg, p < 0.001; SMILE 9.95 ± 1.47 mmHg to 6.76 ± 1.46 mmHg, p < 0.001), with both groups showing a significant decrease from preoperative to 1 month (p < 0.001), and stability from 1 to 3 months (p > 0.05). There were no significant differences between groups in CH or CRF at any time point (p > 0.05).
Patient-Reported Outcomes (PROs)
At the preoperative evaluation, there were no significant differences in any reported symptoms or eye preference between eyes that were to receive TG-LASIK and SMILE. At 3 months, both groups reported an increase in glare compared to the preoperative period. Mild glare symptoms were reported by 68% of TG-LASIK patients and 65% of SMILE patients, compared to 45% in both groups preoperatively. However, no significant intergroup differences were found (p > 0.05). Reported symptoms of halos, rings, or starbursts remained stable from preoperative to 3 months, with 47% of both groups reporting mild symptoms (compared to 42% in TG-LASIK and 44% in SMILE, preoperatively). Both groups had a significant increase in reports of dry eye from preoperative to 3 months (TG-LASIK 50% to 82%; SMILE 47% to 82%, p < 0.001), however there were no significant differences between the groups at 3 months (p > 0.05). At 1 month, 59% of patients preferred their TG-LASIK-treated eye (compared to 33% for the SMILE-treated eye), but at 3 months, 65% of patients reported having no specific eye preference (Fig. 7).
Discussion
In our study, TG-LASIK showed faster visual recovery at 1 day and 1 week compared to SMILE, but both were similarly effective from 1 to 3 months. Yang et al. found TG-LASIK significantly more effective than SMILE at 1 day, with 100% of eyes achieving 20/20 or better (compared to 71% of SMILE) [10]. However, Kanellopoulos showed TG-LASIK significantly more effective at 3 months, with 9.1% gaining two or more lines of UDVA (compared to 4.1% of SMILE) [13] (Table 7). In an earlier retrospective study Moshirfar et al. reported that at 12 months, 10% of TG-LASIK eyes lost one or more lines of UDVA (compared to 19% of SMILE) [12]. The differences in the rate of visual recovery may be due to higher energy levels used in SMILE, as lower energy settings have been associated with improved UDVA on postoperative day 1 [18]. In our study, both groups had excellent safety profiles, with no significant differences. Kang and Zhang et al. similarly found no safety differences between TG-LASIK and SMILE, with over 90% of eyes in both groups experiencing no change or improvement in lines of CDVA 6 months postoperatively [4, 11].
In our study, both platforms demonstrated excellent and comparable predictability, with over 40% of eyes in each group achieving a SEQ within ± 0.13 D of plano. Our findings are comparable to other studies, as Kang et al. showed that 44% of TG-LASIK and SMILE eyes were within ± 0.13 D of target, whereas Zhang et al. reported that 54% of TG-LASIK eyes were within ± 0.13 D of target (compared to 55% of SMILE) [4, 11].
Despite original presumptions that TG-LASIK would reduce total HOAs, our study showed that both groups had a significant increase in total HOAs (27% increase for TG-LASIK vs. 53% increase for SMILE) from the preoperative period to 3 months, but the TG-LASIK group significantly induced less total HOAs, vertical coma, and oblique trefoil than SMILE. Conversely, Yang et al. demonstrated that both groups did not show any significant increases in total HOAs from preoperative to 3 months, but similarly demonstrated that the TG-LASIK group exhibited significantly lower induced total HOAs compared to the SMILE group [10]. Similar to Kang et al., our study showed that SMILE induced significantly more vertical coma than TG-LASIK [11]. TG-LASIK’s customized ablation treatment reduces susceptibility to errors caused by pupil centroid shifts due to changes in pupil size, improving correction of peripheral corneal irregularities [19]. Additionally, SMILE has been shown to cause more vertical decentration than TG-LASIK, specifically around the area of lenticule extraction, potentially contributing to the higher amount of vertical coma [20, 21]. However, newer SMILE platforms such as the VisuMax 800 (Carl Zeiss Meditec AG, Jena, Germany), which was recently approved by the FDA, will offer cyclotorsion and centration control, potentially addressing the induced vertical coma seen with older platforms [22].
Epithelial remodeling after traditional LASIK and SMILE has been well documented. Although controversial, the current proposed mechanism is that changes in corneal curvature from stromal ablation or lenticule extraction may incite corneal epithelial cell migration from the limbus [23, 24]. Changes in epithelial thickness are thought to contribute to myopic regression in patients after corneal refractive surgery [23]. Rocha et al. observed significant central epithelial thickening after LASIK at 1 and 3 months postoperatively [25], whereas Luft et al. observed an increase in CET to 63.0 ± 3.6 µm after SMILE 6 months postoperatively [26]. Our study showed that both TG-LASIK and SMILE groups had significant and comparable increases in amount and variation (max − min CET; SD CET) in epithelial remodeling during the first week and remained relatively stable throughout the rest of the postoperative period. Kanellopoulos similarly demonstrated that CET increased comparably for both groups but noted stability from 3 to 24 months and a significantly greater change in thickness variation (max − min CET) for the TG-LASIK group from 1 to 12 months [14]. Interestingly, our study showed that the SMILE group had a significantly thicker nasal CET than the TG-LASIK group at the 7.0-mm zonal area at 3 months. One study demonstrated that SMILE treatments have a tendency to be decentered nasally due to their lack of cyclotorsion control, resulting in more corneal tissue being removed in that area [21]. This could potentially explain the compensatory epithelial hyperplasia and remodeling observed in our SMILE group in the nasal 7.0 mm zonal area.
Corneal biomechanics is a relatively new area of focus, as studies have found that these properties may play a role in understanding myopic regression after corneal refractive surgery [27, 28]. Prior studies have shown that SMILE provides better biomechanical outcomes than traditional LASIK, likely due to less disturbance of the corneal surface with its flapless approach [27, 28]; however, to the best of our knowledge, no studies have compared TG-LASIK and SMILE with regards to these parameters. Our study showed that although both CH and CRF decreased in both groups postoperatively, there were no significant intergroup differences at any point in time. These results demonstrate that TG-LASIK is not biomechanically inferior to the flapless procedure, SMILE.
The utilization of a contralateral study design enables patients to serve as their own controls, eliminating potential biases arising from differences in healing rates, socioeconomic factors, or environmental influences between subjects. Concerning limitations, we realize that our sample size only consisted of 34 patients (68 eyes) and may limit the generalizability and validity of our outcomes; however, our statistical power for all variables was over 0.8. Another limitation is that a one-dimensional diagnostic tool (ORA) was used to measure CH and CRF, only two of the many biomechanical properties. The lack of comprehensive biomechanical data may limit the validity of our results. Although our study group was only followed up to 3 months postoperatively, it is generally known that visual outcomes stabilize around 3 months after LASIK or SMILE [10, 13]; however, as seen in Kanellopoulos’ study [14], prolonged follow-up of these patients could reveal variations in certain parameters, such as epithelial thickness.
Conclusion
Our study shows that TG-LASIK has a faster postoperative visual recovery than SMILE in the early postoperative period, but both groups achieve excellent and comparable efficacy, safety, and predictability at 3 months. We also demonstrate that both platforms are similar in their effects on the cornea’s biomechanical properties. TG-LASIK also induces less total HOAs, vertical coma, and oblique trefoil than SMILE, likely due to its customized ablation treatment and cyclotorsion control. However, with the introduction of newer SMILE platforms with added cyclotorsion and centration control, further studies comparing the latest advancements in both LASIK and SMILE should be conducted to further evaluate the outcomes described in this study.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036–42. https://doi.org/10.1016/j.ophtha.2016.01.006.
Chen LY, Manche EE. Comparison of femtosecond and excimer laser platforms available for corneal refractive surgery. Curr Opin Ophthalmol. 2016;27(4):316–22. https://doi.org/10.1097/ICU.0000000000000268.
United States Food and Drug Administration. ALLEGRETTOWAVE® Eye-Q Excimer Laser Summary of Safety and Effectiveness Data (P020050/S12). https://www.accessdata.fda.gov/cdrh_docs/pdf2/P020050S012b.pdf. Accessed 4 May 2024
Zhang Y, Sun X, Chen Y. Comparison of corneal optical quality after SMILE, wavefront-optimized LASIK and topography-guided LASIK for myopia and myopic astigmatism. Front Med (Lausanne). 2022;9:870330. https://doi.org/10.3389/fmed.2022.870330.
Steinwender G, Shajari M, Mayer WJ, Kook D, Dirisamer M, Kohnen T. SMILE – small incision lenticule extraction. Klin Monbl Augenheilkd. 2020;237(12):e15–34. https://doi.org/10.1055/a-1291-9041.
Han T, Shang J, Zhou X, Xu Y, Ang M, Zhou X. Refractive outcomes comparing small-incision lenticule extraction and femtosecond laser-assisted laser in situ keratomileusis for high myopia. J Cataract Refract Surg. 2020;46(3):419–27. https://doi.org/10.1097/j.jcrs.0000000000000075.
Klokova OA, Sakhnov SN, Geydenrikh MS, Damashauskas RO. Quality of life after refractive surgery: ReLEx SMILE vs Femto-LASIK. Clin Ophthalmol. 2019;13:561–70. https://doi.org/10.2147/OPTH.S170277.
Dong Z, Zhou X, Wu J, et al. Small incision lenticule extraction (SMILE) and femtosecond laser LASIK: comparison of corneal wound healing and inflammation. Br J Ophthalmol. 2014;98(2):263–9. https://doi.org/10.1136/bjophthalmol-2013-303415.
Ryu IH, Kim BJ, Lee JH, Kim SW. Comparison of corneal epithelial remodeling after femtosecond laser-assisted LASIK and small incision lenticule extraction (SMILE). J Refract Surg. 2017;33(4):250–6. https://doi.org/10.3928/1081597X-20170111-01.
Yang LJ, Liu X, Mi SJ, Sun L, Chen MX. Early visual function outcomes of topography-guided FS-LASIK and SMILE in treatment of myopia and myopic astigmatism. Int J Ophthalmol. 2021;14(3):423–9. https://doi.org/10.18240/ijo.2021.03.15.
Kang EM, Ryu IH, Lee IS, Kim JK, Kim SW, Ji YW. Comparison of corneal higher-order aberrations following topography-guided LASIK and SMILE for myopic correction a propensity score matching analysis. J Clin Med. 2022;11(20):6171. https://doi.org/10.3390/jcm11206171.
Moshirfar M, Somani AN, Motlagh MN, et al. Comparison of FDA-reported visual and refractive outcomes of the toric ICL lens, SMILE, and topography-guided LASIK for the correction of myopia and myopic astigmatism. J Refract Surg. 2019;35(11):699–706. https://doi.org/10.3928/1081597X-20190930-01.
Kanellopoulos AJ. Topography-guided LASIK versus small incision lenticule extraction (SMILE) for myopia and myopic astigmatism: a randomized, prospective, contralateral eye study. J Refract Surg. 2017;33(5):306–12. https://doi.org/10.3928/1081597X-20170221-01.
Kanellopoulos AJ. Comparison of corneal epithelial remodeling over 2 Years in LASIK versus SMILE: a contralateral eye study. Cornea. 2019;38:290–6.
McAlinden C, Pesudovs K, Moore JE. The development of an instrument to measure quality of vision: the quality of vision (QoV) questionnaire. Invest Ophthalmol Vis Sci. 2010;51(11):5537–45. https://doi.org/10.1167/iovs.10-5341.
Gauvin M, Wallerstein A. mEYEstro software: an automatic tool for standardized refractive surgery outcomes reporting. BMC Ophthalmol. 2023;23(1):171. https://doi.org/10.1186/s12886-023-02904-6.
Gauvin M, Wallerstein A. AstigMATIC: an automatic tool for standard astigmatism vector analysis. BMC Ophthalmol. 2018;18(1):255. https://doi.org/10.1186/s12886-018-0920-1.
Hamilton DR, Chen AC, Khorrami R, Nutkiewicz M, Nejad M. Comparison of early visual outcomes after low-energy SMILE, high-energy SMILE, and LASIK for myopia and myopic astigmatism in the United States. J Cataract Refract Surg. 2021;47(1):18–26. https://doi.org/10.1097/j.jcrs.0000000000000368.
Stulting RD, Fant BS, T-CAT Study Group, et al. Results of topography-guided laser in situ keratomileusis custom ablation treatment with a refractive excimer laser. J Cataract Refract Surg. 2016;42(1):11–8. https://doi.org/10.1016/j.jcrs.2015.08.016.
Vingopoulos F, Zisimopoulos A, Kanellopoulos AJ. Comparison of effective corneal refractive centration to the visual axis: LASIK vs SMILE, a contralateral eye digitized comparison of the postoperative result. J Cataract Refract Surg. 2021;47(12):1511–8. https://doi.org/10.1097/j.jcrs.0000000000000687.
Moshirfar M, Herron MS, Cha DS, Santos J, Payne CJ, Hoopes PC. Comparing effective optical zones after myopic ablation between LASIK, PRK, and SMILE with correlation to higher order aberrations. J Refract Surg. 2023;39(11):741–50. https://doi.org/10.3928/1081597X-20231016-02.
Reinstein DZ, Archer TJ, Potter JG, Gupta R, Wiltfang R. Refractive and visual outcomes of SMILE for compound myopic astigmatism with the VISUMAX 800. J Refract Surg. 2023;39(5):294–301. https://doi.org/10.3928/1081597X-20230301-02.
Reinstein DZ, Archer TJ, Gobbe M. Rate of change of curvature of the corneal stromal surface drives epithelial compensatory changes and remodeling. J Refract Surg. 2014;30:799–802.
Le Q, Chen Y, Yang Y, Xu J. Measurement of corneal and limbal epithelial thickness by anterior segment optical coherence tomography and in vivo confocal microscopy. BMC Ophthalmol. 2016;16(1):163. https://doi.org/10.1186/s12886-016-0342-x.
Rocha KM, Krueger RR. Spectral-domain optical coherence tomography epithelial and flap thickness mapping in femtosecond laser-assisted insitu keratomileusis. Am J Ophthalmol. 2014;158:293–301.e1.
Luft N, Ring MH, Dirisamer M, et al. Corneal epithelial remodeling induced by small incision lenticule extraction (SMILE). Invest Oph-thalmol Vis Sci. 2016;57:OCT176–83.
Wu D, Wang Y, Zhang L, Wei S, Tang X. Corneal biomechanical effects: small-incision lenticule extraction versus femtosecond laser-assisted laser in situ keratomileusis. J Cataract Refract Surg. 2014;40:954–62.
Guo H, Hosseini-Moghaddam SM, Hodge W. Corneal biomechanical properties after SMILE versus FLEX, LASIK, LASEK, or PRK: a systematic review and meta-analysis. BMC Ophthalmol. 2019;19(1):167. https://doi.org/10.1186/s12886-019-1165-3.
Acknowledgements
We thank the participants of the study.
Medical Writing, Editorial, and Other Assistance
We would like to acknowledge Steven H. Linn, OD from Hoopes Vision for his assistance with the design of several figures.
Funding
An investigator-initiated study grant was provided by Alcon Laboratories, Inc. (Fort Worth, TX, USA). No funding or sponsorship was received for the publication of this article.
Author information
Authors and Affiliations
Contributions
All authors adhered to ICMJE guidelines and contributed to the design and conception of the work. Kayvon A Moin authored all manuscript drafts and performed data collection and analysis. Garrett N. Manion performed data collection and analysis and contributed to the Methods section. Srujay Pandiri performed data collection and analysis. Phillip C. Hoopes and Majid Moshirfar provided supervision and editing of all manuscript drafts.
Corresponding author
Ethics declarations
Conflict of Interest
Majid Moshirfar is an Editorial Board member of Ophthalmology and Therapy. Majid Moshirfar was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Kayvon A. Moin, Garrett N. Manion, Srujay Pandiri, and Phillip C. Hoopes declare that they have no competing interests.
Ethical Approval
This study received approval from the Salus Institutional Review Board (IORG00005674) and adhered to the tenets of the Declaration of Helsinki of 1964 and its later amendments. All subjects provided written informed consent to participate in this study.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Moin, K.A., Manion, G.N., Pandiri, S. et al. Three-Month Comprehensive Outcomes of Topography-Guided LASIK Versus Keratorefractive Lenticule Extraction (KLEx): A Prospective Contralateral Study. Ophthalmol Ther 13, 2265–2284 (2024). https://doi.org/10.1007/s40123-024-00987-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40123-024-00987-y